Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

Typhoid fever is a significant public health concern with most of the sufferers between 15 and 25 y of age in Nepal. We undertook this study to demonstrate Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT) conjugate vaccine which is non-inferior to Typbar typhoid conjugate vaccine, a Vi po...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dipesh Tamrakar, Pranodan Poudel, Pragya Thapa, Srijana Singh, Amit Khadgi, Sameera Thapa, Rajendra Tamrakar, Anmol Shrestha, Surendra Madhup, Ganesh Kumar Rai, Birendra Prasad Gupta, Tarun Saluja, Sushant Sahastrabuddhe, Rajeev Shrestha
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2024-12-01
Edice:	Human Vaccines & Immunotherapeutics
Témata:	Typhoid conjugate vaccine observer-blind randomized phase III clinical trial
On-line přístup:	https://www.tandfonline.com/doi/10.1080/21645515.2023.2301631
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!